These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8722333)

  • 41. Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation.
    Mahmoud H; Fahmy O; Kamel A; Kamel M; El-Haddad A; El-Kadi D
    Bone Marrow Transplant; 1999 Aug; 24(4):355-8. PubMed ID: 10467322
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Allogeneic peripheral blood progenitor cell transplantation: analysis of short-term engraftment and acute GVHD incidence in 33 cases. allo-PBPCT Spanish Group.
    Urbano-Ispizua A; Solano C; Brunet S; Hernández F; Sanz G; Alegre A; Petit J; Besalduch J; Vivancos P; Díaz MA; Moraleda JM; Carreras E; Ojeda E; de la Rubia J; Benet I; Domingo-Albós A; García-Conde J; Rozman C
    Bone Marrow Transplant; 1996 Jul; 18(1):35-40. PubMed ID: 8831993
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CD34+ cell dose and CD33- subsets: collection and engraftment kinetics in autologous peripheral blood stem cells transplantation.
    Sampol Mayol A; Besalduch Vital J; Galmés Llodrá A; Bargay Lleonart J; Matamoros Flori N; Morey Sureda M; Novo García A; Mascaró Riera M; Gonzaléz Bach E; Martínez García P
    Haematologica; 1998 Jun; 83(6):489-95. PubMed ID: 9676020
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cytokine-mobilized allogeneic peripheral blood stem cell transplants in children result in rapid engraftment and a high incidence of chronic GVHD.
    Levine JE; Wiley J; Kletzel M; Yanik G; Hutchinson RJ; Koehler M; Neudorf S
    Bone Marrow Transplant; 2000 Jan; 25(1):13-8. PubMed ID: 10654008
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Counterflow centrifugation allows addition of appropriate numbers of T cells to allogeneic marrow and blood stem cell grafts to prevent severe GVHD without substantial loss of mature and immature progenitor cells.
    Preijers FW; van Hennik PB; Schattenberg A; Ruijs P; Ploemacher RE; de Witte T
    Bone Marrow Transplant; 1999 May; 23(10):1061-70. PubMed ID: 10373074
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation.
    Baron F; Siquet J; Schaaf-Lafontaine N; Baudoux E; Hermanne JP; Fillet G; Beguin Y
    Haematologica; 2002 Jan; 87(1):78-88. PubMed ID: 11801468
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Single leukapheresis products collected from healthy donors after the administration of granulocyte colony-stimulating factor contain ten-fold higher numbers of long-term reconstituting hematopoietic progenitor cells than conventional bone marrow allografts.
    Theilgaard-Mönch K; Raaschou-Jensen K; Andersen H; Russell CA; Vindeløv L; Jacobsen N; Dickmeiss E
    Bone Marrow Transplant; 1999 Feb; 23(3):243-9. PubMed ID: 10084255
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
    Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The helper T lymphocyte precursor (HTLp) frequency does not predict outcome after HLA-identical sibling donor G-CSF-mobilised peripheral blood stem cell transplantation.
    Healey G; Schwarer AP
    Bone Marrow Transplant; 2002 Sep; 30(6):341-6. PubMed ID: 12235517
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Allogeneic peripheral blood stem cell transplantation (PBSCT) from HLA-identical sibling donors in children with hematological diseases: a single center pilot study.
    Benito AI; Gonzalez-Vicent M; Garcia F; Balas A; Quintero V; Madero L; Vicario JL; Diaz MA
    Bone Marrow Transplant; 2001 Sep; 28(6):537-43. PubMed ID: 11607765
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Granulocyte colony-stimulating factor affects serum levels of soluble interleukin-2 receptors after allogeneic stem cell transplantation.
    Remberger M; Sundberg B
    Haematologica; 2005 Mar; 90(3):427-9. PubMed ID: 15749688
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early lymphocyte recovery is an important determinant of outcome following allogeneic transplantation with CD34+ selected graft and limited T-cell addback.
    Chakrabarti S; Brown J; Guttridge M; Pamphilon DH; Lankester A; Marks DI
    Bone Marrow Transplant; 2003 Jul; 32(1):23-30. PubMed ID: 12815474
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enhanced antileukemic activity of allogeneic peripheral blood progenitor cell transplants following donor treatment with the combination of granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) in a murine transplantation model.
    Hartung G; Zeis M; Glass B; Dreger P; Steinmann J; Schmitz N; Uharek L
    Bone Marrow Transplant; 2003 Jul; 32(1):49-56. PubMed ID: 12815478
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies.
    Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Wang JZ; Gao ZY; Zhang YC; Jiang Q; Shi HX; Lu DP
    Bone Marrow Transplant; 2006 Aug; 38(4):291-7. PubMed ID: 16883312
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Umbilical cord blood for replacement of bone marrow for allogeneic transplantation of hematopoietic stem cells. Stichting Eurocord Nederland].
    Falkenburg JH; Lim FT
    Ned Tijdschr Geneeskd; 1995 Jul; 139(26):1319-22. PubMed ID: 7617048
    [No Abstract]   [Full Text] [Related]  

  • 57. Treatment of normal donors with recombinant growth factors for transplantation of allogeneic blood stem cells.
    Bensinger WI; Buckner CD; Rowley S; Storb R; Appelbaum FR
    Bone Marrow Transplant; 1996 Mar; 17 Suppl 2():S19-21. PubMed ID: 8722328
    [No Abstract]   [Full Text] [Related]  

  • 58. Allogeneic transplantation of peripheral blood progenitor cells.
    Link H; Arseniev L
    Ann Oncol; 1996; 7 Suppl 2():41-5. PubMed ID: 8805948
    [No Abstract]   [Full Text] [Related]  

  • 59. Biological characteristics of cells migrating into the bloodstream.
    Testa NG
    Bone Marrow Transplant; 1996 Mar; 17 Suppl 2():S12-3. PubMed ID: 8722326
    [No Abstract]   [Full Text] [Related]  

  • 60. Developments in allogeneic peripheral blood progenitor cell transplantation.
    Russell NH; Gratwohl A; Schmitz N
    Br J Haematol; 1998 Dec; 103(3):594-600. PubMed ID: 9858206
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.